Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anaphylaxis: clinical aspects.

Albert L Sheffer1

  • 1Brigham and Women's Hospital, Allergy and Clinical Immunology, 850 Boylston St., Suite 540, Chestnut Hill, MA 02467, USA.

Allergy and Asthma Proceedings
|April 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency.

BMC gastroenterology·2014
Same author

Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2013
Same author

Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.

Expert review of clinical immunology·2011
Same author

Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.

The Journal of allergy and clinical immunology·2011
Same author

Ecallantide for the treatment of acute attacks in hereditary angioedema.

The New England journal of medicine·2010
Same author

The diagnosis and management of anaphylaxis practice parameter: 2010 update.

The Journal of allergy and clinical immunology·2010
Same journal

Key factors in the diagnosis of sesame allergy in children.

Allergy and asthma proceedings·2026
Same journal

Immunoglobulin E-mediated pumpkin seed allergy in children: Case series and narrative review with a structured literature search.

Allergy and asthma proceedings·2026
Same journal

Predictors of delayed treatment-free remission with omalizumab in chronic spontaneous urticaria.

Allergy and asthma proceedings·2026
Same journal

The digital front door: A national analysis of U.S. allergy and immunology fellowship program web sites.

Allergy and asthma proceedings·2026
Same journal

The impact of dietary patterns on the risk of asthma in children.

Allergy and asthma proceedings·2026
Same journal

The alpha-gal syndrome: Understanding the role of tick bites, and the delays in severe anaphylaxis.

Allergy and asthma proceedings·2026
See all related articles

Anaphylaxis, a severe allergic reaction, requires prompt treatment with epinephrine. Emerging therapies like anti-IgE antibodies may reduce the frequency and severity of these potentially life-threatening events.

Area of Science:

  • Allergy and Immunology
  • Clinical Medicine

Background:

  • Anaphylaxis is a severe, systemic allergic reaction that can be life-threatening.
  • Symptoms vary widely, from mild flushing to airway obstruction and vascular collapse.
  • Prompt recognition and treatment are crucial for positive outcomes.

Purpose of the Study:

  • To review the characteristics of anaphylaxis and its management.
  • To discuss the role of IgE in anaphylaxis and introduce non-IgE mediated reactions (anaphylactoid).
  • To highlight the increasing incidence of food-induced anaphylaxis, especially peanut allergy.

Main Methods:

  • Literature review of anaphylaxis, IgE-mediated reactions, and anaphylactoid reactions.
  • Discussion of current therapeutic standards, including intramuscular epinephrine.

Related Experiment Videos

  • Exploration of novel therapeutic approaches, such as anti-IgE monoclonal antibodies.

    • Main Results:

    • Anaphylaxis is primarily an IgE-mediated process.
    • Non-IgE mediated reactions are termed anaphylactoid.
    • Peanut-induced anaphylaxis is increasingly prevalent.

    Conclusions:

    • Immediate intramuscular epinephrine is the cornerstone of acute anaphylaxis management.
    • Humanized anti-IgE monoclonal antibody therapy shows promise in reducing the frequency and severity of anaphylactic reactions.
    • Continued research and awareness are vital for managing this critical condition.